Subject: A real-world survey to Assess factors determining use of Dpp4 inhibitors and other oral antidiabetic medications in Indian type 2 diabetes mellitus patients (RED)
Diabetes mellitus (DM) is a worldwide health problem with epidemic proportions and a huge economic burden. The global prevalence of DM in 2019 was estimated to be 9.3% (463 million people) with a projection to rise to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. DM is a major cause of blindness, chronic kidney disease (CKD), stroke, lower extremity amputations and death from coronary heart disease and heart failure (HF).
International Diabetes Federation (IDF 2021) has estimated that India currently has around 74 million people with type 2 diabetes mellitus (T2DM) and the numbers are poised to increase to 125 million in the next 20 years. The ICMR-INDIAB study highlights the enormous burden of NCDs faced by India. It estimates the prevalence of diabetes and prediabetes in India to be 101 million and 136 million, respectively.
DPP-4 inhibitors cause a clinically meaningful reduction in blood glucose, have a low risk of hypoglycemia and a neutral effect on body weight, while their safety profile is overall favorable. They are also easy to use, requiring no dose titration and can be taken at any time of day regardless of meal times. Furthermore, DPP-4 inhibitors exhibit non-glycemic favorable effects including reductions in systolic blood pressure, total cholesterol and triglycerides, as well as improvement in β-cell function. For the above reasons, until recently, they were a safe choice for the up titration of antidiabetic therapy after metformin.
If glucose control targets are not achieved on metformin RSSDI 2022 recommends addition of DPP-4 inhibitor or sodium-glucose cotransporter 2 inhibitors (SGLT2i), or sulfonylurea or thiazolidinediones (TZDs) or Alpha Glucosidase Inhibitors or oral Glucagon like peptide - RA. A similar approach has been advised by other guidelines as well.
Diabetes prevalence is at an alarming level in India, there is a lack of evidence on whether diabetes is adequately managed or not, in alignment with RSSDI 2022 guidelines. At present, there is limited country wide data to obtain meaningful insights on the factors determining use of Dpp4 inhibitors and other oral antidiabetic medications in patients with type 2 diabetes.
The purpose of this survey is to understand the current perceptions about factors determining use of Dpp4 inhibitors and other oral antidiabetic medications in Indian T2DM patients and also help to address the current need gaps to look at potential interventions at patient level.
If you agree to participate, you will need to provide assessment response, on to the standard questionnaire form. A link will be provided for the same on your registered email address.
We trust you and we are partners in safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey.
If you agree to participate in the said study, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})